Precigen, Inc. (PGEN) Misses Q2 EPS by 13c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Precigen, Inc. (PGEN) Reports Phase 1b Study of AG019 ActoBiotics Met Primary Endpoint Assessing Safety and Tolerability
August 10, 2020 7:36 AM EDTPrecigen ActoBio, an innovative clinical-stage biotechnology company focused on a new class of microbe-based therapeutic agents and a wholly-owned subsidiary of Precigen, Inc. (NASDAQ: PGEN), today announced it has met the primary endpoint assessing safety and tolerability in the Phase 1b monotherapy portion of the ongoing Phase 1b/2a clinical study investigating AG019 ActoBiotics for the treatment of early-onset type 1 diabetes (T1D) (clinical trial identifier:... More
Precigen, Inc. (PGEN) Provides Six-month Follow-up Data from Phase I Study of INXN-4001
August 6, 2020 7:54 AM EDTPrecigen Triple-Gene, a clinical stage cardiovascular gene therapy company and majority-owned subsidiary of Precigen, Inc. (Nasdaq: PGEN), today announced six-month follow-up data from the Phase I trial of INXN-4001 (clinical trial identifier: NCT03409627), a multigenic investigational therapeutic candidate under evaluation for the treatment of heart failure.... More
